5-Discussion:
HH is characterized by an increased intestinal iron absorption which
leads to a total-body iron overload.
HH is an autosomal recessive disorder with low penetrance. The C282Y is
a common variant in the HFE gene represented by a guanine to
adenine change at nucleotide 845, which results in the substitution of
cysteine for tyrosine at amino acid 282. Homozygosity for C282Y
represents more than 90% of HH cases [1].
Hemochromatosis is the state of an iron overload and is the result of
pathogenic mutations in genes regulating hepcidin. This process leads to
hyperabsorption of iron and subsequent accumulation of iron in tissues
[1]. HFE C282Y causes a decreased level of hepcidin by
interfering with its physiological upregulation. Decreased levels of
hepcidin mediate an increase in intestinal iron absorption (heme and
non-heme iron). Over years to decades, the amount of absorbed iron
reaches many grams.
In HH, iron absorption ranges between 2-4 mg/day as opposed to 1-2
mg/day in unaffected individuals. Symptoms ensue when iron reaches
levels of 20 grams and above. Symptoms of HH include generalized fatigue
(in the absence of anemia) and pain.
The diagnosis of HH requires a combination of genetic information along
with markers of tissue iron deposition. Three main components establish
the diagnosis of HH: a ferritin level greater than 300 ng/mL (in males
and post-menopausal females) and greater than 200 ng/mL (for
pre-menopausal women), a TSAT greater than 45% and homozygosity for
C282Y.
Homozygosity for HFE C282Y is not always associated with iron
overload, which has been coined as C282Y/C282Y genotype without
iron-overload [1].
Iron can deposit in the liver, heart, pancreas and pituitary gland.
Hepatic iron overload results in hepatomegaly, elevated hepatic
transaminases and hepatic fibrosis that can eventually develop into
liver cirrhosis.
Cardiac iron overload causes dilated cardiomyopathy, sick sinus syndrome
and arrhythmias that can lead to sudden cardiac death.
Iron can deposit in endocrine organs. For instance, pancreatic iron
overload leads to diabetes mellitus (DM) type II. Likewise, iron
deposition in the pituitary gland can cause hypopituitarism resulting in
secondary hypogonadism and secondary hypothyroidism. Secondary
hypogonadism results in decreased libido and impotence in males [2].
Iron overload in the central nervous systems results in generalized
cognitive impairment [3].
HH-associated arthropathy results in arthritis and arthralgias whereby
the joints of the hands are commonly affected [4].
Iron deposition in the skin causes skin hyperpigmentation termed as
“bronze skin”.
HH can also engender porphyria cutanea tarda (PCT) and osteoporosis.
Iron overload increases the risk of cancer. For example, hepatic iron
overload can cause hepatocellular carcinoma (HCC) [5].
There is a causality between iron overload and susceptibility to
infections [6]. For instance, patients with iron overload are at
increased risk for Yersinia enterocolitica and Vibrio
vulnificus infections. Yersinia enterocolitica is a
gram-negative organism found in wildlife and domestic livestock.
Transmission to humans is foodborne. The virulence of Yersinia
enterocolitica is heightened in the presence of excess iron. This is
why Yersinia enterocolitica is a siderophilic bacterium [6].
MRI is appropriate if serum ferritin is greater than 800 to 1,000 ng/mL.
A liver biopsy is not required for diagnosis and it is replaced by MRI
for estimation of iron stores.
Management of HH is through iron removal and normalization of iron
stores. Removing excess iron by phlebotomy is the mainstay of treatment.
Therapeutic phlebotomy is effective and devoid of toxicities provided
that the patient is not severely anemic.
In adults, therapeutic phlebotomy is recommended once weekly initially
and can be performed more frequently in the setting of severe
iron-overload. Performing phlebotomy twice weekly is possible provided
that Hb level remains in the safe range (>11 g/dL).
Erythrocytapheresis and iron chelation are alternatives to phlebotomy.
In erythrocytapheresis, red blood cells (RBCs) are removed in an
isovolumic manner and the patient’s plasma is returned in a closed
circuit.
Iron chelation is represented by the usage of oral or parenteral
iron-chelating agents. They are commonly used in hemoglobinopathies,
such as sickle cell disease and thalassemia.
The typical schedule for phlebotomy is once weekly until target ferritin
is reached in accordance with anemia status and patient’s tolerance. The
number of phlebotomies can be estimated and determined by Hb and
ferritin levels that should be monitored periodically. Target ferritin
level is 50 to 100 ng/mL. Of note, iron-deficiency should be avoided.
Once target is met, patients should be monitored with maintenance
phlebotomies or expectant management guided by the ferritin level.
The prognosis of HH is dictated by the severity of iron overload at
diagnosis and extent of iron removal. Normal survival is defined as a
ferritin level less than 1,000 ng/mL at diagnosis.
Major causes of death are cirrhosis, diabetes and HCC.
Yersinioses are zoonotic infections of domestic and wild animals. Humans
are incidental hosts. Three species have been identified: Yersinia
pestis , Yersinia enterocolitica and Yersinia
pseudotuberculosis [7].
Y. pestis causes plague, whereas Y. enterocolitica andY. pseudotuberculosis cause yersiniosis that results in diarrheal
illness.
Transmission of Y. enterocolitica is largely foodborne
(raw/undercooked pork products) and occasionally waterborne. Y.
enterocolitica can also be transmitted through blood transfusions of
packed red blood cells [8].
Y. enterocolitica is ferrophilic and has a predilection for
patients with derangements of iron metabolism, such as hemochromatosis,
cirrhosis, aplastic anemia, sickle cell disease, DM, malignancy and
immunosuppression.
Patients get infected by consumption of uncooked or raw pork products
and untreated water.
Y. enterocolitica is a facultative, gram negative and anaerobic
coccobacillus [9].
Virulent subtypes are O:3, O:5,27, O:8 and O:9.
Clinical manifestations of Y. enterocolitica are acute febrile
enterocolitis and pseudo-appendicitis syndrome.
Yersiniosis can have gastrointestinal (GI) and extra-intestinal
complications and post-infectious sequelae [10].
Acute yersiniosis has an incubation period of 4 to 6 days [11].
Clinical manifestations of yersiniosis are fever, abdominal pain,
diarrhea, nausea and vomiting [12].
A localized right upper quadrant pain is a diagnostic clue for
yersiniosis [12]. Yersiniosis can also cause pharyngitis, bacteremia
and sepsis [13].
Patients with iron-overload states are more prone to develop bacteremia
and sepsis.
GI complications of yersiniosis are perforation, toxic megacolon and
paralytic ileus [14].
Extra-intestinal complications are liver abscess, endocarditis and
osteomyelitis.
Post-infectious sequelae are erythema nodosum and reactive arthritis,
specifically in patients with HLA-B27 tissue type [15].
Diagnosis is isolation of the pathogen by stool culture [16].Y. enterocolitica requires a specific growth medium, which is the
CIN agar [17].
Adequate hydration and electrolytes correction are the mainstay
treatments of mild enterocolitis. There is no rationale behind using
antibiotics for mild enterocolitis due to the lack of benefit [18].
The only benefit is that the usage of antibiotics decreases stool
shedding of Y. enterocolitica [19].
When indicated, commonly used antibiotics are ciprofloxacin and
levofloxacin. Alternative agents are doxycycline and
trimethoprim-sulfamethoxazole [18]. The duration of treatment is 5
days.
Intravenous (IV) antibiotics are reserved for cases of bacteremia,
sepsis, high fevers and grossly bloody stools [20].
Ceftriaxone 2 g IV once daily in combination with gentamicin (5
mg/Kg/day) is the mainstay of IV antibiotics treatment. The duration of
treatment is at least 3 weeks. Ciprofloxacin 400 mg IV twice daily is an
alternative to ceftriaxone [20].
Longer treatment duration is warranted in patients with compromised
immunity and extra-intestinal infections. Patients should be switched to
oral treatment once clinical improvement is achieved [13].
In conclusion, physicians should exclude the diagnosis of HH when
approaching a patient with yersiniosis in the setting of
hyper-ferritinemia and elevated iron saturation. A prompt diagnosis is
warranted for timely management that can be conducive to better clinical
outcomes and favorable prognosis.